AVCN.F Stock Overview A commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Avicanna Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Avicanna Historical stock prices Current Share Price CA$0.20 52 Week High CA$0.53 52 Week Low CA$0.17 Beta 1.66 1 Month Change -2.55% 3 Month Change -15.46% 1 Year Change -24.36% 3 Year Change -69.27% 5 Year Change -90.79% Change since IPO -92.61%
Recent News & Updates Avicanna Inc. announced that it has received CAD 0.80001 million in funding Nov 05
Avicanna Inc. announced that it has received CAD 1.986208 million in funding Aug 29
Avicanna Announces United States Patent and Trademark Office Issuance of Patent SEDDS Technology Jun 19
Avicanna Inc., Annual General Meeting, Jul 10, 2024 Jun 05
Avicanna Inc. Announces Results of Study in Patients with Epidermolysis Bullosa May 15 Avicanna Inc. announced that it has received CAD 2.125584 million in funding Apr 19
See more updates Avicanna Inc. announced that it has received CAD 0.80001 million in funding Nov 05
Avicanna Inc. announced that it has received CAD 1.986208 million in funding Aug 29
Avicanna Announces United States Patent and Trademark Office Issuance of Patent SEDDS Technology Jun 19
Avicanna Inc., Annual General Meeting, Jul 10, 2024 Jun 05
Avicanna Inc. Announces Results of Study in Patients with Epidermolysis Bullosa May 15 Avicanna Inc. announced that it has received CAD 2.125584 million in funding Apr 19
Avicanna Inc. Announces Completion of Topical Gel Observational Real-World Evidence Study Apr 10
Avicanna Inc Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation Mar 28
Avicanna Inc. to Report Fiscal Year 2023 Results on Apr 01, 2024 Mar 27
Avicanna Inc. Obtains Its First Indication-Specific Drug Registration with Trunerox Feb 15 Avicanna Inc. announced that it has received CAD 0.888128 million in funding Dec 05
Avicanna Announces Appointment of Paul Fornazzari to Board of Directors Nov 14
Avicanna Inc. to Report Q3, 2023 Results on Nov 14, 2023 Nov 02
Avicanna Inc. Provides Update on the Successful Launch of MyMedi.ca Oct 12
Avicanna Inc. Announces Retirement of Chandra Panchal, PhD from the Board of Directors Sep 02 Avicanna Inc. announced that it has received CAD 1.455 million in funding Aug 03
Avicanna Inc. (TSX:AVCN) completed the acquisition of Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc. Aug 02
Avicanna Inc. (TSX:AVCN) entered into definitive Asset Purchase Agreement to acquire Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc. for CAD 2.6 million. May 30
Avicanna LATAM S.A.S. Announces Step Down of Lucas Nosiglia as President, Effective January 31, 2023 Dec 31 Avicanna Inc. announced that it has received CAD 1.769097 million in funding
Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the Rho Phytotm Cbg Transdermal Gel Topical Product Dec 15
Avicanna Inc. Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market Nov 30 Avicanna Inc. announced that it has received CAD 0.626763 million in funding Nov 12
Avicanna Files Complete Patent Specifications Relating to A Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy Oct 21
Avicanna Introduces a New Medical Cannabis Education Online Portal, "Avicenna Academy" for Health Care Professionals Oct 19
Assad Kazeminy Retires as Director of Avicanna Inc Sep 02 Avicanna Inc. announced that it has received CAD 2.782302 million in funding Aug 18
Avicanna Inc., Annual General Meeting, Aug 31, 2022 Jul 06
An unknown buyer acquired 63 percent stake in Sativa Nativa S.A.S. from Avicanna Inc. (TSX:AVCN) for CAD 0.81 million. Jun 25
Avicanna Inc. Announces Chief Financial Officer Changes May 13 Avicanna Inc. announced that it has received CAD 1.473826 million in funding from Ei.Ventures, Inc. May 08
Avicanna Inc. announced that it has received CAD 2.523568 million in funding Apr 01
Avicanna Inc. Provides Consolidated Revenue Guidance for the Fourth Quarter, Full Year 2021 and Full Year 2022 Feb 03 Avicanna Inc. announced that it expects to receive CAD 1.3008 million in funding Jan 30
Avicanna Inc. Launches Its Clinically Backed CBD Derma-Cosmetics Brand, Pura H&W, in the United States in Partnership with Red White and Bloom Dec 23
Avicanna and Harrington Wellness Launch Re+Play™ Branded Cbd Topicals Products in Canada Dec 21
Avicanna Inc. Files Patent to Protect its Advanced Oral Cannabinoid Platform and its Applications for Neurological Diseases Dec 07
Avicanna Files US Patent Application for a Novel Cannabinoid Formulation in Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy Sep 25
Avicanna Inc. announced that it has received CAD 2.118 million in funding Aug 20
Avicanna Inc. announced that it expects to receive CAD 2 million in funding Aug 05
Avicanna and Bio-Gate Complete First Phase of Development on Cannabidiol (CBD) and Microsilver BG™ Based Skin Care Products for Global Commercialization Jun 30
Avicanna Inc. Expands The Canadian Rho Phyto Product Offerings with the Addition of THC-Free High CBD Oral and Sublingual Formulation Across Medical and Adult Use Channels Jun 16
Avicanna Inc.’s Pura Earth to Be Launched in Adult-Use and Medical Channels Across Canada in Second Quarter of 2021 May 27
Avicanna Inc. announced that it has received CAD 5.6 million in funding Mar 05 Shareholder Returns AVCN.F US Pharmaceuticals US Market 7D -9.9% 1.3% 0.6% 1Y -24.4% 8.0% 23.8%
See full shareholder returns
Return vs Market: AVCN.F underperformed the US Market which returned 23.8% over the past year.
Price Volatility Is AVCN.F's price volatile compared to industry and market? AVCN.F volatility AVCN.F Average Weekly Movement 21.3% Pharmaceuticals Industry Average Movement 10.5% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.6% 10% least volatile stocks in US Market 3.1%
Stable Share Price: AVCN.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AVCN.F's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome.
Show more Avicanna Inc. Fundamentals Summary How do Avicanna's earnings and revenue compare to its market cap? AVCN.F fundamental statistics Market cap US$25.23m Earnings (TTM ) -US$4.72m Revenue (TTM ) US$17.27m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) AVCN.F income statement (TTM ) Revenue CA$24.90m Cost of Revenue CA$13.73m Gross Profit CA$11.17m Other Expenses CA$17.97m Earnings -CA$6.80m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.062 Gross Margin 44.86% Net Profit Margin -27.32% Debt/Equity Ratio 0.9%
How did AVCN.F perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/28 17:54 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Avicanna Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Rahul Sarugaser Raymond James Ltd.
Show 0 more analysts 
